Trial
NCT02900651
Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Diffuse Large B-cell Lymphoma
Intervention
MAK683
Why stopped
The decision of early termination was made due to business reasons, and was not based on any safety or tolerability concerns for MAK683
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-08-11